Clinical trials: Squamous Oesophageal Cancer
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma
- Trial name
- P102 (NCT02013154)
- Testing
- DKN-01 150 mg, Paclitaxel, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 151 people
- Sponsor
- Leap Therapeutics, Inc.
Esophageal Carcinoma
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05476380
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients…
- Trial name
- ESO-shanghai31 (NCT07697859)
- Testing
- Two arms adopt local intervention administered at distinct timings.
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06468670
- Testing
- sintilimab，programmed death 1 monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital